Biofina Diagnostics S.L has been awarded with a Seal of Excellence by the European Commission following the presentation of its project proposal UROBEST ´UROthelial carcinoma Biomarker based diagnostic tEST´ Submitted under the Horizon 2020’s SME instrument phase 2 call H2020-SMEInst-2014-2015 (H2020-SMEINST-2-2015) of 25 November 2015 in the area of Clinical research for the validation of biomarkers and/or diagnostic medical devices.
After being evaluated by an international panel of independent experts UROBEST was successful in a highly competitive evaluation process as an innovative project proposal. This means passing all stringent Horizon 2020 assessment thresholds for the 3 award criteria: EXCELLENCE, IMPACT, QUALITY AND EFFICIENCY OF IMPLEMENTATION required to receive funding from the EU budget Horizon 2020.
The European Commission recommends this proposal for funding by other sources since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.
Metas Biotech consultants have contributed to the preparation of this application to the SME Instrument phase 2 Grant and have since been advising Biofina Diagnostics in the definition of their business plan.
